Visual disorders associated with omeprazole and their relation to CYP2C19 polymorphism.
Risk factors for patients developing visual disturbances in association with proton pump inhibitors are unknown. As omeprazole is substantially metabolized by polymorphic CYP2C19, we retrospectively identified and genotyped patients who experienced this adverse reaction. Among 29 patients, we found two poor metabolizers (PMs) of CYP2C19. The PM genotype does not appear to be a risk factor for omeprazole-associated visual disorders.
Lutz
Markus
M
Division of Clinical Pharmacology, University Hospital Tübingen, Germany.
Schwab
Matthias
M
Griese
Ernst-Ulrich
EU
Marx
Claudia
C
Müller-Oerlinghausen
Bruno
B
Schönhöfer
Peter S
PS
Meisner
Christoph
C
Gleiter
Christoph H
CH
Eichelbaum
Michel
M
Mörike
Klaus
K
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D000897:Anti-Ulcer Agents / Q000009:adverse effects*; D001189:Aryl Hydrocarbon Hydroxylases; D065731:Cytochrome P-450 CYP2C19; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics*; D004791:Enzyme Inhibitors / Q000009:adverse effects*; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D006899:Mixed Function Oxygenases / Q000235:genetics*; D009853:Omeprazole / Q000009:adverse effects*; D010641:Phenotype; D011110:Polymorphism, Genetic; D054328:Proton Pump Inhibitors; D012189:Retrospective Studies; D014786:Vision Disorders / Q000139:chemically induced* / Q000201:enzymology / Q000235:genetics*
D000897:Anti-Ulcer Agents; D004791:Enzyme Inhibitors; D054328:Proton Pump Inhibitors; D003577:Cytochrome P-450 Enzyme System; D006899:Mixed Function Oxygenases; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D009853:Omeprazole